期刊文献+

规律吸入噻托溴铵对慢性阻塞性肺疾病稳定期患者的长期疗效 被引量:1

Long-term therapeutic effect of regular inhalation of tiotropium bromide on stable phase chronic obstructive pulmonary disease patients
原文传递
导出
摘要 噻托溴铵是一种长效的吸人型支气管扩张剂,通过选择性地拮抗M3受体发挥作用,吸人一次,疗效可维持24h以上。目前已有的临床证据表明,规律使用该药对中、重度慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)具有良好疗效,除了改善肺功能参数外,它在改善呼吸困难、生活质量、减少急性加重次数和住院次数方面要优于安慰剂、异丙托溴胺和长效β2受体激动剂。本品用药方便,安全性好,可作为一线和基础药物长期用于稳定期COPD患者。噻托溴铵的远期疗效及其与其他药物联合治疗的作用还有待进一步研究。 Tiotropium bromide is a kind of long acting bronchodilators by inhalation which can selectively rival M3 receptor. A single dose of tiotropium bromide can maintain therapeutic effect more than 24 hours. Clinical evidence confirmed that regular application of tiotropium bromide had good curative effect on moderate-to-severe chronic obstructive pulmonary disease(COPD). Apart from ameliorating pulmonary function parameters,tiotropium bromide could also ease dyspnea, improve life quality, reduce the times of acute exacerbation and hospitalization,whose therapeutic effect outweigh placebo,ipratropium and long-term β2 receptor agonist. Tiotropium bromide is convenient and safe to apply, which is suitable for long-term therapy to stable phase COPD patients as a basic medicine. The prostective efficacy of tiotropium bromide and its therapeutic alliance with other medicine are still left to investigate.
作者 殷凯生
出处 《国际呼吸杂志》 2009年第3期163-167,共5页 International Journal of Respiration
关键词 噻托溴铵 慢性阻塞性肺疾病 长期疗效 Tiotropium bromide Chronic obstructive pulmonary disease Long-term therapeutic effect
  • 引文网络
  • 相关文献

参考文献41

  • 1Regional COPD Working Group. COPD prevalence in 12 Asia- Pacifie countries and regions: projections based on the COPD prevalence estimation model. Respirology, 2003,8 : 192-198.
  • 2周玉民,刘升明,吕嘉春,郑劲平,钟南山,冉丕鑫.中国慢性阻塞性肺疾病患病率调查方法的研究设计[J].中华流行病学杂志,2006,27(9):814-818. 被引量:43
  • 3Olin JL. Tiotropium: an inhaled anticholinergic for chronic obstructive pulmonary disease. Am J Health Syst Pharm, 2005,62 : 1263-1269.
  • 4Barnes PJ. The pharmacological properties of tiotropium. Chest,2000,117(2 Suppl) :63S-66S.
  • 5O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methaeholine-induced bronehoeonstrietion in asthma. Am J Respir Crit Care Med,1996,154(4 Pt 1):876-880.
  • 6Hanania NA. Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes. Clin Ther, 2007,29 : 2121-2133.
  • 7Currie GP,Rossiter C, Miles SA, et al. Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease. Pulm Pharmacol Ther, 2006, 19:112-119.
  • 8Donohue JF,van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest, 2002,122 : 47-55.
  • 9de Luise C, Lanes SF, Jacobsen J, et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol,2007,22 : 267-272.
  • 10Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax, 2006,61 : 854-862.

二级参考文献31

  • 1Gasaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease[J]. Eur Respir J, 2002, 19:217-224.
  • 2Vincken W, Van Noord JA, Greefhorst APM, et al. lmproved health outcomes in patients with COPD during 1 year treatment with tiotropium[J]. Eur Respir J, 2002,19:209-216.
  • 3Donohue JF, Van Noord JA, Bateman ED, et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol[J]. Chest, 2002,122:47 - 55.
  • 4Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes in a 6-month placebo controlled trial of once-daily tiotropium compared with twice-daily salmeterol in patients with COPD[J]. Thorax, 2003,58:399 - 404.
  • 5O' Donnell DE, Magnussen H, Aguilaniu B, et al. Tiotropium improves exercise tolerance in COPD [J]. Am J Respir Crit Care Med,2002, 165:227.
  • 6Tashkin PT, Cooper CB. The role of long-acting bronchodilators in the management of COPD[J]. Chest, 2004, 125:249-259.
  • 7Regional COPD Working Group.COPD prevalence in 12 Asia-Pacific countries and regions:projections based on the COPD prevalence estimation model.Respiratory,2003,8:192-198.
  • 8Sin DD,Stafinski.The impact of chronic obstructive pulmonary disease on work loss in the United States.Am J Respir Crit Care Med,2002,165:704-707.
  • 9Ferris BG.Epidemiology Standardization Project (American Thoracic Society).Am Rev Respir Dis 1978,118:1-20.
  • 10The Research Arm of the BC Cancer Agency.Lung Health Study Questionaire 1999-2001.http://www.bccrc.ca/downloads/ci/lc02 _ questionnaire.doc.Accessed Nov 20,2002.

共引文献63

引证文献1

相关主题

;
使用帮助 返回顶部